`
`Attorney Docket No. 2004__1016A
`
`Serial No. 10/500,354
`
`Filed June 30, 2004
`
`:
`
`:
`
`AQUEOUS LIQUID PREPARATIONS AND
`LIGHT-STABILIZED AQUEOUS LIQUID
`PREPARATIONS
`
`Group Art Unit 1614
`
`Examiner Charlesworth E. Rae
`
`Mail Stop: Amendment
`
`SUPPLEMENTAL AMENDMENT
`
`Commissioner for Patents
`
`P.O. Box 1450
`
`Alexandria, VA 22313-1450
`
`Sir:
`
`Further to Applicants’ Response dated October 9, 2007, please amend the above-
`
`identified application as follows:
`
`MYLAN EX. 1020, Page 1
`
`MYLAN Ex. 1020, Page 1
`
`
`
`Amendments to the Specification
`
`Page 10, lines 5-17, please rewrite as follows:
`
`The appearance after light irradiation did not change from that immediately after
`
`preparation and was pale yellow and clear for Formulation 10 (pH 4) and Formulation 11 (pH
`
`8.5) comprising sodium chloride. In addition, the appearance did not change from gag
`
`immediately after preparation and was colorless and clear for Formulation 12 having a
`
`bepotastine besilate concentration of 0.1 w/v%. These results and the results of Formulation 7
`
`(pH 6.8) in Experimental Example 2 indicate that addition of sodium chloride, which is a water-
`
`soluble metal chloride, improves light stability of bepotastine besilate at pH 4-8.5. In addition,
`
`they indicate that the light-stability of bepotastine besilate is improved in the concentration range
`
`of 0.1 w/v% - 1.5 w/v%.
`
`MYLAN EX. 1020, Page 2
`
`MYLAN Ex. 1020, Page 2
`
`
`
`Amendments to the Claims
`
`1. (Currently amended)
`
`An aqueous liquid preparation comprising (+)—(S)—4—[4-[(4-
`
`chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid
`
`addition salt thereof, and a water-soluble metal chloride in an agueous solution.
`
`2. (Original)
`
`The aqueous liquid preparation of claim 1, wherein the metal chloride has
`
`a concentration selected from the range of a lower limit concentration of 0.15 w/v% and an upper
`
`limit concentration of 1.5 w/v%.
`
`3. (Previously presented)
`
`The aqueous liquid preparation of claim 1, wherein the metal
`
`chloride is at least one kind selected from sodium chloride, potassium chloride and calcium
`
`chloride.
`
`4. (Previously presented)
`
`The aqueous liquid preparation of claim 1, wherein the (+)-(S)-4-
`
`[4-[(4—chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or the pharmacologically
`
`acceptable acid addition salt thereof has a concentration selected from the range of a lower limit
`
`concentration of 0.1 w/v% and an upper limit concentration of 2.0 w/v%.
`
`5. (Previously presented)
`
`The aqueous liquid preparation of claim 1, which is an acid
`
`addition salt of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid.
`
`6. (Original)
`
`The aqueous liquid preparation of claim 5, wherein the acid addition salt is
`
`monobenzenesulfonate.
`
`7. (Previously presented)
`
`The aqueous liquid preparation of claim 1, wherein the aqueous
`
`liquid preparation has a pH in the range of 4-8.5.
`
`8. (Previously presented)
`
`The aqueous liquid preparation of claim 1, which is an eye drop.
`
`9. (Previously presented)
`
`The aqueous liquid preparation of claim 1, which is a nasal drop.
`
`MYLAN EX. 1020, Page 3
`
`MYLAN Ex. 1020, Page 3
`
`
`
`10. (Currently amended)
`
`An aqueous eye drop comprising (+)-(S)-4-[4-[(4-
`
`chloropheny1)(2-pyridyl)methoxy]piperidino]butyric acid monobenzenesulfonate and sodium
`
`chloride at not less than 0.2 w/v% and not more than 0.8 w/v% in an agueous solution.
`
`11. (Original)
`
`A method of light-stabilizing (+)-(S)-4-[4-[(4-ch1orophenyl)(2-
`
`pyridyl)methoxy]piperidino]butyric acid in an aqueous solution, which comprises adding a
`
`water-soluble metal chloride to an aqueous solution comprising (+)-(S)-4-[4-[(4-
`
`chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid
`
`addition salt thereof.
`
`MYLAN EX. 1020, Page 4
`
`MYLAN Ex. 1020, Page 4
`
`
`
`REMARKS
`
`A further editorial change has been effected to the paragraph appearing on page 10, line
`
`Claims 1 and 10 have been further amended to specify that the preparation is “in an
`
`aqueous solution”. This is responsive to the Examiner’s statement on page 4, lines 3-4 of the
`
`Action that no patentable weight is given to the preamble of the former claims.
`
`In addition, there is submitted herewith an executed Rule 132 Declaration of Dr.
`
`Higashiyama. The Declaration sets forth the experiments of Experimental Examples 1-4 of the
`
`specification. As discussed in Applicants’ response of October 9, 2007, these experiments show
`
`the unexpected effect of this invention.
`
`In view of the foregoing, favorable consideration and allowance is solicited.
`
`Respectfully submitted,
`
`Masayo HIGASHIYAMA
`
`Bygai
`Warren M. Cheek
`
`Registration No. 33,367
`Attorney for Applicant
`
`WMC/dlk
`
`Washington, D.C. 20006-1021
`Telephone (202) 721-8200
`Facsimile (202) 721-8250
`November 13, 2007
`
`MYLAN EX. 1020, Page 5
`
`MYLAN Ex. 1020, Page 5